Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
M Husain, SC Bain, OK Jeppesen… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aim To investigate the effects of semaglutide versus comparators on major adverse
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …
cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] …
Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2
diabetes (T2D) available in subcutaneous (sc) and oral formulations. Two cardiovascular …
diabetes (T2D) available in subcutaneous (sc) and oral formulations. Two cardiovascular …
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the …
LA Leiter, SC Bain, I Hramiak, E Jódar… - Cardiovascular …, 2019 - Springer
Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in …
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
SP Marso, SC Bain, A Consoli… - … England Journal of …, 2016 - Mass Medical Soc
Background Regulatory guidance specifies the need to establish cardiovascular safety of
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial
SC Bain, O Mosenzon, R Arechavaleta… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aims To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation
of a glucagon‐like peptide‐1 receptor agonist. Materials and methods PIONEER 6 is a …
of a glucagon‐like peptide‐1 receptor agonist. Materials and methods PIONEER 6 is a …
Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6
MA Nauck, DR Quast - Frontiers in endocrinology, 2021 - frontiersin.org
To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
M Husain, AL Birkenfeld, M Donsmark… - … England Journal of …, 2019 - Mass Medical Soc
Background Establishing cardiovascular safety of new therapies for type 2 diabetes is
important. Safety data are available for the subcutaneous form of the glucagon-like peptide …
important. Safety data are available for the subcutaneous form of the glucagon-like peptide …
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the …
VR Aroda, A Ahmann, B Cariou, F Chow… - Diabetes & …, 2019 - Elsevier
In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor
management reduces the likelihood of late-stage diabetic complications. Guidelines …
management reduces the likelihood of late-stage diabetic complications. Guidelines …
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic …
DK McGuire, RP Busui, J Deanfield… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To describe the design of the SOUL trial (Semaglutide cardiOvascular oUtcomes triaL)
and the baseline clinical data of its participants. Materials and methods In SOUL, the effects …
and the baseline clinical data of its participants. Materials and methods In SOUL, the effects …
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes
VR Aroda, U Erhan, P Jelnes, JJ Meier… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim Glucagon‐like peptide‐1 receptor agonists improve glycaemic control: some are now
available as oral and subcutaneous formulations, and some have indications for reducing …
available as oral and subcutaneous formulations, and some have indications for reducing …